Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)
- 14 February 2012
- journal article
- research article
- Published by SAGE Publications in Journal of the Renin-Angiotensin-Aldosterone System
- Vol. 13 (3), 387-393
- https://doi.org/10.1177/1470320311434818
Abstract
Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.Keywords
This publication has 33 references indexed in Scilit:
- Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular DiseaseJournal of the American Society of Nephrology, 2011
- High glucose and renin release: the role of succinate and GPR91Kidney International, 2010
- Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial InfarctionNew England Journal of Medicine, 2004
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With NephropathyCirculation, 2004
- Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAALKidney International, 2004
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatmentDiabetologia, 1994
- EARLY AGGRESSIVE ANTIHYPERTENSIVE TREATMENT REDUCES RATE OF DECLINE IN KIDNEY FUNCTION IN DIABETIC NEPHROPATHYThe Lancet, 1983